Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new strategy to prevent cervical cancer: community follow-up for HPV shots

NCT ID NCT07807202

Prevention Sponsor: Muso Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether proactive follow-up by community health workers can increase HPV vaccination coverage among adolescent girls in Mali and Côte d'Ivoire. Researchers compare girls who receive home visits and digital reminders to those getting standard outreach. The goal is to see if this approach helps more girls get vaccinated and get vaccinated sooner. After an initial period, all participants will receive the follow-up program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Proactive community-based follow-up by community health workers with digital decision support
What this could lead to
If effective, this approach could increase HPV vaccination rates and reduce future cervical cancer risk in these countries.
What could go wrong
The trial is early and results may not show a clear benefit. Also, the intervention depends on local health systems and may not be scalable or sustainable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

17,188 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 14 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female adolescent residing within a participating Muso Health catchment area in Mali or Côte d'Ivoire * Age-eligible for HPV vaccination under national immunization guidelines during the study period: 10 years of age in Mali; 9 to 14 years of age in Côte d'Ivoire * Not yet age-eligible at study launch but expected to reach the nationally recommended vaccination age during the study period Exclusion Criteria: * Residence outside the defined study catchment areas * Not identifiable or registered in the Community Health Toolkit (CHT) programmatic data system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Papillomavirus infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Papillomavirus infections Uterine cervical neoplasms

Contacts and locations

Locations

  • Bankas, Yirimadio, and Bakorobabougou health areas

    Bamako, Mali

  • Madinani health district and Diape catchment area

    Abidjan, Côte d’Ivoire

More trials for these conditions

Other studies related to the condition(s) this trial covers.